Please Wait
Applying Filters...
Menu
Xls
2D Structure
Also known as: 835-31-4, 2-(naphthalen-1-ylmethyl)-4,5-dihydro-1h-imidazole, Naphthizine, Antan, Nafazolin, Ciba 2020/r
Molecular Formula
C14H14N2
Molecular Weight
210.27  g/mol
InChI Key
CNIIGCLFLJGOGP-UHFFFAOYSA-N
FDA UNII
H231GF11BV

An adrenergic vasoconstrictor agent used as a decongestant.
1 2D Structure

2D Structure

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-(naphthalen-1-ylmethyl)-4,5-dihydro-1H-imidazole
2.1.2 InChI
InChI=1S/C14H14N2/c1-2-7-13-11(4-1)5-3-6-12(13)10-14-15-8-9-16-14/h1-7H,8-10H2,(H,15,16)
2.1.3 InChI Key
CNIIGCLFLJGOGP-UHFFFAOYSA-N
2.1.4 Canonical SMILES
C1CN=C(N1)CC2=CC=CC3=CC=CC=C32
2.2 Other Identifiers
2.2.1 UNII
H231GF11BV
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Afazol Grin

2. Ak Con

3. Ak-con

4. Albalon

5. All Clear

6. Clear Eyes

7. Colirio Alfa

8. Hydrochloride, Naphazoline

9. Idril

10. Miraclar

11. Monohydrochloride, Naphazoline

12. Nafazair

13. Naphazoline Hydrochloride

14. Naphazoline Monohydrochloride

15. Naphazoline Nitrate

16. Naphcon

17. Naphcon Forte

18. Nitrate, Naphazoline

19. Optazine

20. Pensa, Vasoconstrictor

21. Privin

22. Privine

23. Proculin

24. Siozwo

25. Tele Stulln

26. Tele-stulln

27. Vasoclear

28. Vasocon

29. Vasocon Regular

30. Vasoconstrictor Pensa

31. Vasonit

2.3.2 Depositor-Supplied Synonyms

1. 835-31-4

2. 2-(naphthalen-1-ylmethyl)-4,5-dihydro-1h-imidazole

3. Naphthizine

4. Antan

5. Nafazolin

6. Ciba 2020/r

7. 2-(1-naphthylmethyl)-2-imidazoline

8. 1h-imidazole, 4,5-dihydro-2-(1-naphthalenylmethyl)-

9. Nafazair

10. 2-(naphthyl-(1')-methyl)imidazolin

11. Naphcon

12. Naphazoline (inn)

13. 2-imidazoline, 2-(1-naphthylmethyl)-

14. H231gf11bv

15. Clearine

16. 2-(1-naphthylmethyl)-4,5-dihydro-1h-imidazole

17. 2-[(naphthalen-1-yl)methyl]-4,5-dihydro-1h-imidazole

18. Nafazolina [dcit]

19. Naphazolinum

20. Nafazolina

21. Nafazoline

22. Nafazoline [spanish]

23. Naphazolinum [latin]

24. Naphazoline [inn]

25. Naphazoline [inn:ban]

26. Naphazolinum [inn-latin]

27. Rhinazine

28. Alpha-naphthylmethyl Imidazoline

29. Chembl1706

30. 2-(alpha-naphthylmethyl)-imidazoline

31. Nafazolin (tn)

32. 4,5-dihydro-2-(1-naphthylmethyl)imidazole

33. Enamine_000333

34. 10061-11-7

35. 2-(naphthyl-(1')-methyl)imidazolin [german]

36. Einecs 212-641-5

37. Brn 0151864

38. Unii-h231gf11bv

39. Imidin

40. Privine (salt/mix)

41. Sanorin (salt/mix)

42. Spectrum_000975

43. Naphazoline [mi]

44. Prestwick0_000046

45. Prestwick1_000046

46. Prestwick2_000046

47. Prestwick3_000046

48. Spectrum2_001054

49. Spectrum3_000513

50. Spectrum4_000068

51. Spectrum5_001424

52. Chembl761

53. Naphazoline [vandf]

54. Naphazoline [mart.]

55. Schembl34532

56. Bspbio_000171

57. Bspbio_002065

58. Kbiogr_000595

59. Kbioss_001455

60. Naphazoline [who-dd]

61. 5-23-08-00293 (beilstein Handbook Reference)

62. Cid_11079

63. Divk1c_000456

64. Spbio_001008

65. Spbio_002092

66. Bpbio1_000189

67. Gtpl5509

68. Dtxsid3048449

69. Chebi:93363

70. Kbio1_000456

71. Kbio2_001455

72. Kbio2_004023

73. Kbio2_006591

74. Kbio3_001565

75. Ninds_000456

76. .alpha.-naphthylmethyl Imidazoline

77. Hms1394p03

78. Hms2090d15

79. Zinc119717

80. Bbl012612

81. Bdbm50001922

82. Mfcd00066737

83. Stk300042

84. Akos000295230

85. Ccg-250339

86. Db06711

87. 2-(.alpha.-naphthylmethyl)-imidazoline

88. 2-(1-naphthalenylmethyl)-2-imidazoline

89. Idi1_000456

90. Ncgc00016506-01

91. Ncgc00016506-02

92. Ncgc00016506-03

93. Ncgc00016506-04

94. Ncgc00016506-05

95. Vs-03410

96. Sbi-0051454.p003

97. Db-050155

98. Hy-111326

99. Cs-0034952

100. Ft-0725973

101. D08253

102. Ab00053505-11

103. Ab00053505-12

104. Ab00053505_13

105. Ab00053505_14

106. 550n992

107. A840596

108. L000878

109. Q415433

110. 2-(1-naphthalenylmethyl)-4,5-dihydro-1h-imidazole

111. 2-(1-naphthylmethyl)-4,5-dihydro-1h-imidazole #

112. Brd-k77641333-003-05-7

113. Brd-k77641333-003-15-6

114. Brd-k77641333-003-25-5

115. Z56762888

116. 2-(1-naphthylmethyl)-4,5-dihydro-1h-imidazole;naphazoline

117. 2-naphthalen-1-ylmethyl-4,5-dihydro-1h-imidazole; Hydrochloride

2.4 Create Date
2005-03-25
3 Chemical and Physical Properties
Molecular Weight 210.27 g/mol
Molecular Formula C14H14N2
XLogP32.1
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count1
Rotatable Bond Count2
Exact Mass210.115698455 g/mol
Monoisotopic Mass210.115698455 g/mol
Topological Polar Surface Area24.4 Ų
Heavy Atom Count16
Formal Charge0
Complexity272
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 1  
Drug NameNaphcon-a
Active Ingredient<a class="pubchem-internal-link CID-11079" href="/compound/Naphazoline%20hydrochloride">Naphazoline hydrochloride</a>; <a class="pubchem-internal-link CID-52821
Dosage FormSolution/drops
RouteOphthalmic
Strength0.025%; 0.3%
Market StatusOver the Counter
CompanyAlcon

4.2 Drug Indication

Naphazoline is indicated for use as OTC eyedrops for ocular vasoconstriction or as a nasal preparation for nasal congestion.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Naphazoline is a sympathomimetic alpha adrenergic agonist that acts to vasoconstrict nasal or ocular arterioles, resulting in reduced congestion at the site of administration.


5.2 MeSH Pharmacological Classification

Nasal Decongestants

Drugs designed to treat inflammation of the nasal passages, generally the result of an infection (more often than not the common cold) or an allergy related condition, e.g., hay fever. The inflammation involves swelling of the mucous membrane that lines the nasal passages and results in inordinate mucus production. The primary class of nasal decongestants are vasoconstrictor agents. (From PharmAssist, The Family Guide to Health and Medicine, 1993) (See all compounds classified as Nasal Decongestants.)


Adrenergic alpha-Agonists

Drugs that selectively bind to and activate alpha adrenergic receptors. (See all compounds classified as Adrenergic alpha-Agonists.)


5.3 ATC Code

R01AA08

S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355


R - Respiratory system

R01 - Nasal preparations

R01A - Decongestants and other nasal preparations for topical use

R01AA - Sympathomimetics, plain

R01AA08 - Naphazoline


R - Respiratory system

R01 - Nasal preparations

R01A - Decongestants and other nasal preparations for topical use

R01AB - Sympathomimetics, combinations excl. corticosteroids

R01AB02 - Naphazoline


S - Sensory organs

S01 - Ophthalmologicals

S01G - Decongestants and antiallergics

S01GA - Sympathomimetics used as decongestants

S01GA01 - Naphazoline


5.4 Absorption, Distribution and Excretion

Absorption

Absorption data for naphazoline are scarce but imidazoline compounds in general are weakly basic and lipophilic, with high bioavailability from the gastrointestinal tract.


Route of Elimination

Imidazoline compounds undergo some hepatic metabolism but a large fraction of the dose may be excreted unchanged in the urine. Urinary excretion is higher with more acidic urine.


Volume of Distribution

Distribution data for naphazoline are scarce but imidazoline compounds are distributed throughout the body, and can cross the blood-brain barrier.


Clearance

Clearance data for naphazoline is unavailable.


5.5 Metabolism/Metabolites

Metabolism data for naphazoline are scarce. Imidazoline compounds undergo some hepatic metabolism but a large fraction of the dose may be excreted unchanged in the urine.


5.6 Biological Half-Life

Half life has not been determined but effects last for 4 to 8 hours. Other imidazoline compounds have half lives varying from 2 to 12 hours.


5.7 Mechanism of Action

Naphazoline is a vasoconstrictor that functions by stimulating alpha adrenergic receptors in arterioles leading to decreased congestion at the site of administration. Naphazoline causes the release of norepinephrine in sympathetic nerves. Norepinephrine binds to alpha adrenergic receptors and causes vasoconstriction. Naphazoline is also a mild beta adrenergic receptor agonist, which can cause rebound vasodilation after the alpha adrenergic stimulation has ended. Naphazoline's release of norepinephrine also triggers a negative feedback loop which decreases production of norepinephrine, which can lead to rhinitis medicamentosa after long term use when naphazoline is stopped.